XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Clinical treatment programs – US $ 16 $ 40
Total Revenues 16 40
Costs and Expenses:    
Production costs 10 8
Research and development 1,080 1,951
General and administrative 2,545 3,815
Total Costs and Expenses 3,635 5,774
Operating loss (3,619) (5,734)
Gain (Loss) on investments 27 (92)
Interest and other income 11 81
Interest Expense and Other Finance Costs (124) (72)
Net Loss $ (3,705) $ (5,817)
Basic loss per share $ (0.05) $ (0.12)
Diluted loss per share $ (0.05) $ (0.12)
Weighted average shares outstanding basic 70,329,869 49,458,023
Weighted average shares outstanding diluted 70,329,869 49,458,023